About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Health Care and Law
Is the traditional randomized controlled trial on the way out? Efforts are under way to promote a new trial design, known as the adaptive trial.
Robert I. Field, JD, MPH, PhD
A regimen of insulin glargine (Lantus) and insulin glulisine (Apridra) is compared with carbohydrate counting to lower glycosylated hemoglobin levels; colesevelam (Welchol), a lipid-lowering agent, benefits glycemic control; and an oral agent, vildagliptin (Galvus), targets pancreatic islet dysfunction.
Reuben B. David
Aliskiren (Rasilez) in combination with hydrochlorothiazide is beneficial for uninterrupted blood pressure control over 24 hours, and valsartan (Diovan) is used for reducing high-sensitivity C-reactive protein levels.
Continuing Education Credit
An Overview of Overactive Bladder and Its Pharmacological Management with a Focus on Anticholinergic Drugs
Older and newer agents, as well as nonpharmacological options, are reviewed along with a discussion of urinary incontinence, bladder physiology, and patient education.
George DeMaagd, PharmD, BCPS, and Jeffrey D. Geibig, PharmD
David Nash, MD, MBA, discusses an experimental concept in which an “unsales” force would use evidence-based tools in an effort to encourage doctors to focus on lowering drug costs in Pennsylvania (e.g., by prescribing generic drugs).
David Nash, MD, MBA
Pressure Builds to Untie the FDA’s Hands on Generics: High Drug Prices Still Fuel Public–Hence Political–Pressure
Stephen Barlas comments on the pressure to increase the
number of generic versions of brand-name drugs and one of the constraints facing the FDA, namely Citizen Petitions.
Matthew Grissinger, RPh, FASCP, examines the inappropriate use of IV sterile water.
Matthew Grissinger, RPh, FASCP
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.
The authors review a drospirenone/estradiol combination (Angeliq) to treat menopausal symptoms.
Nasya Ezell, PharmD Candidate, Alicia Hardy, PharmD Candidate, Marlon Honeywell, PharmD, Angela Singh, PharmD, Jessica Warthen, PharmD, and Patty Ghazvini, PharmD